The content of this evidence summary was up to date in February 2021. See summaries of product characteristics (SPCs), British national formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date information.
Remsima for subcutaneous injection (Celltrion Healthcare Hungary) is a biosimilar monoclonal antibody of infliximab that inhibits the activity of tumour necrosis factor (TNF)‑alpha. It received a marketing authorisation for managing rheumatoid arthritis in December 2019 and received a license extension for Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis in July 2020. This evidence summary focuses on the license extension for Crohn's disease and ulcerative colitis only.